An Heart Therapeutics
Biotechnology, 5 Penn Plaza 23rd Fl, New York, 10001, United States, 51-200 Employees
Phone Number: +12*********
Who is ANHEART THERAPEUTICS
AnHeart Therapeutics is a clinical-stage global biopharmaceutical group company developing a broad pipeline of novel precision oncology therapeutics with high unmet medical needs. Its lea...
Read More
-
Headquarters: 5 Penn Plaza 23rd Fl, New York, New York, 10001, United States
-
Date Founded: 2018
-
Employees: 51-200
-
Revenue: $10 Million to $25 Million
-
Active Tech Stack: See technologies
Industry: Biotechnology
SIC Code: 2834
|
NAICS Code: 325412 |
Show More
Does something look wrong? Fix it. | View contact records from ANHEART THERAPEUTICS
AnHeart Therapeutics Org Chart and Mapping
Email
Phone
Sign in to CIENCE GO Data to uncover contact details
Free credits every month
Frequently Asked Questions Regarding AnHeart Therapeutics
Answer: AnHeart Therapeutics's headquarters are located at 5 Penn Plaza 23rd Fl, New York, 10001, United States
Answer: AnHeart Therapeutics's phone number is +12*********
Answer: AnHeart Therapeutics's official website is https://anhearttherapeutics.com
Answer: AnHeart Therapeutics's revenue is $10 Million to $25 Million
Answer: AnHeart Therapeutics's SIC: 2834
Answer: AnHeart Therapeutics's NAICS: 325412
Answer: AnHeart Therapeutics has 51-200 employees
Answer: AnHeart Therapeutics is in Biotechnology
Answer: AnHeart Therapeutics contact info: Phone number: +12********* Website: https://anhearttherapeutics.com
Answer: AnHeart Therapeutics is a clinical-stage global biopharmaceutical group company developing a broad pipeline of novel precision oncology therapeutics with high unmet medical needs. Its lead asset, taletrectinib, is a best-in-class next-generation ROS1 inhibitor currently in Phase 2 trials for the first-line TKI-naïve and second-line TKI-pre-treated patients with ROS1 fusion positive non-small cell lung cancer (NSCLC). The Company’s pipeline also includes AB-218, a mIDH1 inhibitor in Phase 2 trials with good brain penetration for multiple solid tumors with mIDH1 mutations and AB-329, an AXL inhibitor in Phase 1 studies to be used in combination with checkpoint inhibitor or chemotherapies in NSCLC or other solid tumors.
Premium Sales Data for Prospecting
-
Sales data across over 200M records
-
Up-to-date records (less decayed data)
-
Accurate Email Lists (real-world tested)
-
Powerful search engine and intuitive interface
Get Full Access
Sign in to CIENCE GO Data to uncover contact details
Free credits every month